Innovation and Patent Law Reform: Hearings Before the Subcommittee on Courts, Civil Liberties, and the Administration of Justice of the Committee on the Judiciary, House of Representatives, Ninety-eighth Congress, Second Session, on H.R. 3285, H.R. 3286, and H.R. 3605 ... March 28, April 26, and June 6, 27, 1984, 2. daļaU.S. Government Printing Office, 1985 - 2897 lappuses |
No grāmatas satura
1.–5. rezultāts no 84.
999. lappuse
... firm by the applicant , which would precede ANDA approval in every case by six months cr more , would enable the pioneer manufacturer to protect its patent rights through judicial remedies and would not require FDA to divert its limited ...
... firm by the applicant , which would precede ANDA approval in every case by six months cr more , would enable the pioneer manufacturer to protect its patent rights through judicial remedies and would not require FDA to divert its limited ...
1020. lappuse
... firms favor it as is ? A. The bill combines two concepts , on patent restoration and on generic drug approvals . The companies believe that the combined legislation fails to achieve a proper balance between the two issues and would not ...
... firms favor it as is ? A. The bill combines two concepts , on patent restoration and on generic drug approvals . The companies believe that the combined legislation fails to achieve a proper balance between the two issues and would not ...
1055. lappuse
... trials and owned by U.S. firms has steadily dropped from a yearly average of 60 in the mid - 1960s to about 25 a year now . In contrast , the number of compa- rable foreign - owned new drugs has remained almost constant 1055.
... trials and owned by U.S. firms has steadily dropped from a yearly average of 60 in the mid - 1960s to about 25 a year now . In contrast , the number of compa- rable foreign - owned new drugs has remained almost constant 1055.
1056. lappuse
... firms self - originate fewer new drugs than before 1960 and are increas- ingly dependent on foreign firms for licensing new products , though licensed products still make up less than half of drug introductions by small firms . By any ...
... firms self - originate fewer new drugs than before 1960 and are increas- ingly dependent on foreign firms for licensing new products , though licensed products still make up less than half of drug introductions by small firms . By any ...
1075. lappuse
... firms informa- tion which costs many millions of dollars to obtain and which can be used to obtain approval to ... firm's foreign competitors . Competitors will copy the data and submit them to foreign drug regulatory agencies when they ...
... firms informa- tion which costs many millions of dollars to obtain and which can be used to obtain approval to ... firm's foreign competitors . Competitors will copy the data and submit them to foreign drug regulatory agencies when they ...
Saturs
946 | |
977 | |
988 | |
1095 | |
1118 | |
1134 | |
1140 | |
1142 | |
1506 | |
1516 | |
1570 | |
1577 | |
1594 | |
1612 | |
1656 | |
1657 | |
1145 | |
1183 | |
1197 | |
1206 | |
1210 | |
1215 | |
1245 | |
1269 | |
1284 | |
1294 | |
1307 | |
1335 | |
1341 | |
1360 | |
1403 | |
1435 | |
1482 | |
1663 | |
1672 | |
1680 | |
1725 | |
1739 | |
1756 | |
1767 | |
1786 | |
1819 | |
1824 | |
1835 | |
1855 | |
1867 | |
1871 | |
1886 | |
1888 | |
1909 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
1962 Amendments 2d Cir Adkins agreement ANDA antitrust Appeals assignment available as prior Bass benefits beta blockers bill Bolar Circuit claims clinical testing commercial company/client compensation Congress Consent Judgment contract Corp corporation costs decision or settlement defendant Dextrose diazepam disclosed disclosure district court drug application electrolyte employed inventor employee estoppel federal filed firms grant Hoffmann-La Roche I.V. Solution industry Injection innovation invalid Kastenmeier Labs Lear doctrine legislation license licensee estoppel licensor litigation manufacture ment monopoly NAME TRADE NAME NCEs NDAS APPROVED patent application patent infringement patent issued patent law Patent Office patent protection patent rights patent system patent validity period pharmaceutical plaintiff preliminary injunction prior art prior invention question reduced to practice regulation relief result Roche royalties Sodium Sodium Chloride statute Supp supra note Tablet tion trade secret Trademark U.S. patent United United Kingdom Zenith
Populāri fragmenti
1551. lappuse - A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.
1573. lappuse - ... before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.
1510. lappuse - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
1191. lappuse - A patent shall be presumed valid. Each claim of a patent (whether in independent, dependent, or multiple dependent form) shall be presumed valid independently of the validity of other claims; dependent or multiple dependent claims shall be presumed valid even though dependent upon an invalid claim.
1485. lappuse - States, or (c) he has abandoned the invention, or (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States...
1330. lappuse - The several courts vested with jurisdiction of cases arising under the patent laws shall have power to grant injunctions according to the course and principles of courts of equity, to prevent the violation of any right secured by patent, on such terms as the court may deem reasonable...
1485. lappuse - ... b. the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or c.
1160. lappuse - In determining whether an accused device or composition infringes a valid patent, resort must be had in the first instance to the words of the claim. If accused matter falls clearly within the claim, infringement is made out and that is the end of it.
1153. lappuse - States, or (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent...
1465. lappuse - ... obligation to assign the application. All such individuals have a duty to disclose to the Office information they are aware of which is material to the examination of the application. Such information is material where there is a substantial likelihood that a reasonable examiner would consider it important in deciding whether to allow the application to issue as a patent.